Intervertebral discitis is a rare, but recognised complication of systemic candidaemia. Once diagnosed, treatment often consists of a prolonged course of amphotericin B and/or fluconazole. We report a case of Candida discitis, successfully treated with fluconazole and 5-flucytosine.
A 48-year-old Caucasian woman underwent a computerised tomography (CT) scan of chest to investigate chronic cough. This showed an incidental finding of inflammation of the inter-vertebral disc between sixth and seventh thoracic vertebrae. 3 months prior to this admission, she underwent a laparotomy for division of adhesions. Her postoperative period was complicated by severe sepsis requiring admission to the intensive care unit. Blood cultures at that time grew Staphylococcus aureus and Candida and she was treated with vancomycin, amphotericin B and fluconazole.
During the admission, she complained of mid-thoracic pain and did not have any features of systemic infection. She was on a combination of four different analgesics for the management of the pain. On examination, she had minimal tenderness over the mid-thoracic region without neurological signs. Investigations showed a C-reactive protein of 11 mg/l, normal white cell count and bone profile. Blood cultures were sterile and Candida antigen was not detected. Protein electrophoresis was normal and urine was negative for Bence-Jones proteins. An isotope bone scan showed a hot-spot at sixth and seventh thoracic vertebrae disc (T6/7) and an MRI scan revealed a high signal in the same area with surrounding oedema and softtissue swelling, suggestive of discitis (Fig. 1) . A CT-guided biopsy showed inflammatory cells comprising plasma cells and periodic-acid Schiff staining confirmed the presence of Candida hyphae.
Fluconazole 400 mg once a day orally was commenced, but she continued to complain of pain even after 2 weeks of treatment. Treatment was switched to intravenous fluconazole and IV 5-flucytosine for 2 weeks that resulted in symptomatic improvement and she was continued on oral fluconazole 400 mg for a further 4 weeks.
Candida discitis is a rare complication of systemic candidaemia and is thought to spread haematogenously [1] . To date, \60 such cases are reported. Invasive Candida infections have increased significantly over the past two decades [2] and are commonly seen in immunosuppressed patients and intravenous drug users. The lack of typical inflammatory response and insidious course of the disease can make the diagnosis difficult.
The ideal duration for treatment of fungal discitis has not yet been established, and current practice is to continue therapy until clinical symptoms and inflammatory markers have normalised and/or imaging shows resolution of inflammation. Other treatment options include surgical intervention especially in cases of neurological compromise [3, 4] .
Increasing resistance of Candida species has also been noted. Candida discitis is increasingly being noticed in severely ill patients with candidaemia previously exposed to azoles [2] . Of note, no relationship between the duration of the initial treatment of candidaemia and the subsequent occurrence of late complications has been established [5] . Evidence points towards amphotericin IV being the firstline agent of choice [5] . However, as amphotericin is nephrotoxic, some authors prefer fluconazole due to its favourable side-effect profile [6] . Currently, flucytosine is recommended for use in combination therapy in resistant cases of chronic disseminated candidiasis [2] .
This case shows that it is important to consider fungal discitis in patients with back pain and a history of candidaemia. 5-Flucytosine might be a useful agent in treating Candida discitis in an era where resistance to other antifungal agents is increasing. 
